MSH2 and neoplasm: Importantly, the comparison of the tumor risk between the EPCAM and EPCAM-MSH2 deletion carriers indicates that the difference in endometrial cancer risk relates to the mosaic inactivation of MSH2 and not to a constitutive loss of EPCAM[20].